# EDGAR Filing Document

**Accession Number:** 0001840706
**File Stem:** 0000950103-23-002203
**Filing Date:** 2023-2
**Character Count:** 8426
**Document Hash:** c3489824cd3e2ada595fd663dae97fe2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-23-002203.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0000950103-23-002203

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230213

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOPHiA GENETICS SA
- **CENTRAL INDEX KEY:** 0001840706
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40627
- **FILM NUMBER:** 23614448

**BUSINESS ADDRESS:**
- **STREET 1:** RUE DU CENTRE 172, CH-1025
- **CITY:** SAINT-SULPICE
- **STATE:** V8
- **ZIP:** 00000
- **BUSINESS PHONE:** 41 21 694 10 60

**MAIL ADDRESS:**
- **STREET 1:** RUE DU CENTRE 172, CH-1025
- **CITY:** SAINT-SULPICE
- **STATE:** V8
- **ZIP:** 00000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2023.

**Commission File Number: 001-40627**

**SOPHiA GENETICS SA**

**(Exact name of registrant as specified in its charter)**

**Rue du Centre 172**

**CH-1025 Saint-Sulpice**

**Switzerland**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SOPHiA GENETICS SA** | **SOPHiA GENETICS SA** |
| Date: February 13, 2023 |  |  |
|  | By: | /s/ Daan van Well |
|  | Name: | Daan van Well |
|  | Title: | Chief Legal Officer |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Press release dated February 13, 2023 |

---

## Exhibit 99.1

**Exhibit 99.1**

**SOPHiA GENETICS Expands Partnership with AstraZeneca to include Multimodal Approaches for Cancer Drug Development**

*The expanded partnership aims to leverage the global SOPHiA DDM™ platform and multimodal algorithmic capabilities to lead a new era of precision oncology by improving early patient identification and diagnosis, optimizing clinical development, and accelerating adoption of innovative medications along the care pathway* 

**Boston and Lausanne, Switzerland** – February 13, 2023 – SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their <u>multimodal technology and expertise</u> to the biopharmaceutical company's oncology portfolio. The multimodal approach will go beyond a single data modality, combining radiomics analysis of medical imaging data, molecular data, digital pathology, clinical and biologic data for a more comprehensive assessment of multimodal signatures leveraging proprietary AI and machine learning technology. Together, the companies will examine ways to accelerate clinical trials, support evidence generation for market access, and improve clinical decision-making, helping clinicians to select the best possible treatments.

SOPHiA GENETICS is able to support this vision in practice today. In parallel, SOPHiA GENETICS launched its own real-world DEEP-Lung-IV clinical study to leverage its multimodal machine learning-powered analytics capabilities to identify multimodal predictive signatures of response to immunotherapy for patients with advanced lung cancer.

"AstraZeneca is a global leader in innovative oncology therapeutics and has built one of the most diverse and robust oncology portfolios and R&D pipelines in the industry. Building on our existing partnership with AstraZeneca, notably to expand <u>access to HRD testing,</u> we are incredibly excited to deepen our collaboration to multimodal approaches that will further enable their precision oncology capabilities" said **Peter Casasanto, Chief BioPharma Officer of SOPHiA GENETICS**.

"We see AstraZeneca as a visionary partner willing to invest in the next generation of data sciences and technology capabilities at scale to usher in a new area of data-driven medicine. We are incredibly excited to further integrate science and technology in our joint pursuit of transformative impact on patient outcomes" said **Dr. Philippe Menu, Chief Medical Officer SOPHiA GENETICS.**

"Multimodality aims to harness the power of advanced AI and machine learning models by integrating multiple data modalities to obtain key insights which inform prognosis and response

to therapy at the individual patient level. This approach is synergistic with AstraZeneca's focus on developing personalized cancer treatment and has the potential to elevate precision oncology, currently driven by genomic-based biomarkers, into a truly multimodal connected health ecosystem," said **Greg Rossi, Senior Vice President, Oncology Europe & Canada, AstraZeneca.**

**About SOPHiA GENETICS** <br> SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit <u>SOPHiAGENETICS.COM</u>, or connect on <u>Twitter</u>, <u>LinkedIn</u>**,** <u>Facebook</u>, and <u>Instagram</u>. **Where others see data, we see answers.**

*SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.*

*SOPHiA GENETICS Forward-Looking Statements:*

*This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations* 

*or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.*

<br> **Media Contact:** <br> Nick Puleo

npuleo@comsint.com

**Investor Contact:**

Katherine Bailon

IR@sophigenetics.com